Down-regulation of p73 correlates with high histological grade in Japanese with breast carcinomas

Chinese Medical Journal

Volumn 124, Issue 15, 2011, Pages 2275-2278

  Du, Cai Wen ^a   Kimijima, Izo ^b   Otake, Toru ^b   Abe, Rikiya ^b   Takenoshita, Seiichi ^b   Zhang, Guo Jun ^a  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Loss of heterozygosity; P53; P73; Polymorphism

Indexed keywords

MESSENGER RNA; PROTEIN P73;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; JAPANESE; MUTATIONAL ANALYSIS; OPEN READING FRAME; P73 GENE; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA; DNA-BINDING PROTEINS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79961054481     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.15.006     Document Type: Article

References (24)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
2. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
3. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian[correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389: 191-194.
4. Callahan R. Genetic alterations in primary breast cancer. Breast Cancer Res Treat 1989; 13: 191-203.
5. Nagai H, Negrini M, Carter SL, Gillum DR, Rosenberg AL, Schwartz GF, et al. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1995; 55: 1752-1757.
6. Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A, et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res Treat 2001; 66: 183-190.
7. Shishikura T, Ichimiya S, Ozaki T, Nimura Y, Kageyama H, Nakamura Y, et al. Mutational analysis of the p73 gene in human breast cancers. Int J Cancer 1999; 84: 321-325.
8. Yamamoto T, Oda K, Kubota T, Miyazaki K, Takenouti Y, Nimura Y, et al. Expression of p73 gene, cell proliferation and apoptosis in breast cancer: immunohistochemical and clinicopathological study. Oncol Rep 2002; 9: 729-735.
9. Nimura Y, Mihara M, Ichimiya S, Sakiyama S, Seki N, Ohira M, et al. p73, a gene related to p53, is not mutated in esophageal carcinomas. Int J Cancer 1998; 78: 437-440.
10. Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 1997; 27: 371-377.
11. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998; 9: 897-903.
12. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG Jr. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998; 18: 6316-6324.
13. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998; 58: 1380-1383.
14. Hu Z, Miao X, Ma H, Tan W, Wang X, Lu D, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer 2005;114:455-460.
15. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999; 18: 1629-1633.
16. Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick D, Polychronakos C, et al. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene 1998; 17: 1739-1741.
17. Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis 2005;26:103-107.
18. Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, et al. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol 2008; 128: 1585-1588.
19. Schwartz DI, Lindor NM, Walsh-Vockley C, Roche PC, Mai M, Smith DI, et al. p73 mutations are not detected in sporadic and hereditary breast cancer. Breast Cancer Res Treat 1999; 58: 25-29.
20. Dominguez G, Silva J, Silva JM, Garcia JM, Miralles C, Rodriguez O, et al. Clinicopathological characteristics of breast carcinomas with allelic loss in the p73 region. Breast Cancer Res Treat 2000; 63: 17-22.
21. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10: 626-633.
22. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24: 805-815.
23. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-2691.
24. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12: 1564-1577.